US Edition
Published • loading... • Updated
What's Going On With Bristol Myers Squibb Stock Friday? - Bristol-Myers Squibb (NYSE:BMY)
Bristol Myers Squibb paid $1.5 billion to acquire Orbital Therapeutics and expand its cell therapy portfolio targeting autoimmune diseases with the experimental OTX-201 candidate.
- On Oct 10, 2025, Bristol Myers Squibb announced in Bengaluru it will acquire privately-held Orbital Therapeutics for $1.5 billion in cash, pending regulatory review.
- Seeking to broaden beyond blockbusters, BMS acquired Orbital's proprietary RNA platform and OTX-201, an in vivo CAR T candidate targeting autoimmune diseases.
- Most of the $1.5 billion cash payment and milestone structure is payable at closing, with remaining payments tied to preclinical and early clinical milestones for OTX-201.
- On Oct 10, BMY stock ticked up about 0.3%, suggesting investors had largely priced in or were cautiously optimistic about the company's first major acquisition this year beyond Eliquis and Revlimid.
- Orbital aims to begin human trials of OTX-201 in early 2026, after which its collaboration with Beam Therapeutics will continue amid a ~$200B global autoimmune therapeutics market by 2031.
Insights by Ground AI
22 Articles
22 Articles
BMS Joins the In Vivo Cell Therapy Chase With $1.5B Orbital Therapeutics Acquisition
Startup Orbital Therapeutics brings Bristol Myers Squibb an in vivo cell therapy in development for treating autoimmune disease. With the deal, BMS joins AstraZeneca, AbbVie, and Gilead Sciences in turning to M&A as a way to get in vivo cell therapy assets and technologies. The post BMS Joins the In Vivo Cell Therapy Chase With $1.5B Orbital Therapeutics Acquisition appeared first on MedCity News.
Bristol Myers Squibb to buy Orbital Therapeutics for $1.5B
·Washington, United States
Read Full Article
Bristol Myers buys Orbital Therapeutics for $1.5 billion
Drugmaker Bristol Myers Squibb said today it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash, aiming to diversify from legacy products facing competition from generic drugs.
·Ireland
Read Full Article
Coverage Details
Total News Sources22
Leaning Left2Leaning Right1Center7Last UpdatedBias Distribution70% Center
Bias Distribution
- 70% of the sources are Center
70% Center
L 20%
C 70%
Factuality
To view factuality data please Upgrade to Premium
